SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune… Read more
SAB Biotherapeutics Inc (SABS) - Net Assets
Latest net assets as of September 2025: $165.07 Million USD
Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) has net assets worth $165.07 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($183.45 Million) and total liabilities ($18.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $165.07 Million |
| % of Total Assets | 89.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | -33.42% |
| 10-Year Change | N/A |
| Growth Volatility | 51.2 |
SAB Biotherapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how SAB Biotherapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SAB Biotherapeutics Inc (2019–2024)
The table below shows the annual net assets of SAB Biotherapeutics Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $25.97 Million | -54.68% |
| 2023-12-31 | $57.30 Million | +84.49% |
| 2022-12-31 | $31.06 Million | -19.43% |
| 2021-12-31 | $38.55 Million | -1.17% |
| 2020-12-31 | $39.01 Million | +1791.90% |
| 2019-12-31 | $-2.31 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SAB Biotherapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9206665700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $935.00 | 0.00% |
| Other Comprehensive Income | $-135.41K | -0.52% |
| Other Components | $150.27 Million | 578.65% |
| Total Equity | $25.97 Million | 100.00% |
SAB Biotherapeutics Inc Competitors by Market Cap
The table below lists competitors of SAB Biotherapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TBS Energi Utama Tbk PT
JK:TOBA
|
$77.82 Million |
|
Helius Minerals Limited
V:HHH
|
$77.82 Million |
|
Cystech Electronics Corp
TWO:6651
|
$77.84 Million |
|
Unimot S.A
WAR:UNT
|
$77.89 Million |
|
EREUF
PINK:EREUF
|
$77.74 Million |
|
HI Mobility Berhad
KLSE:5335
|
$77.74 Million |
|
Axactor SE
OL:ACR
|
$77.73 Million |
|
5QQ
F:5QQ
|
$77.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SAB Biotherapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 57,299,441 to 25,969,576, a change of -31,329,865 (-54.7%).
- Net loss of 34,105,309 reduced equity.
- Other comprehensive income decreased equity by 161,830.
- Other factors increased equity by 2,937,274.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-34.11 Million | -131.33% |
| Other Comprehensive Income | $-161.83K | -0.62% |
| Other Changes | $2.94 Million | +11.31% |
| Total Change | $- | -54.68% |
Book Value vs Market Value Analysis
This analysis compares SAB Biotherapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.45x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.53 | $4.07 | x |
| 2020-12-31 | $14.44 | $4.07 | x |
| 2021-12-31 | $14.10 | $4.07 | x |
| 2022-12-31 | $7.14 | $4.07 | x |
| 2023-12-31 | $10.38 | $4.07 | x |
| 2024-12-31 | $2.80 | $4.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SAB Biotherapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -131.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2579.03%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.70x
- Recent ROE (-131.33%) is below the historical average (-43.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -261.07% | 0.19x | 0.00x | $-8.76 Million |
| 2020 | 51.57% | 36.42% | 0.98x | 1.45x | $16.22 Million |
| 2021 | -44.47% | -28.16% | 0.75x | 2.10x | $-21.00 Million |
| 2022 | -60.34% | -78.40% | 0.47x | 1.64x | $-21.85 Million |
| 2023 | -73.64% | -1884.50% | 0.03x | 1.46x | $-47.92 Million |
| 2024 | -131.33% | -2579.03% | 0.03x | 1.70x | $-36.70 Million |
Industry Comparison
This section compares SAB Biotherapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SAB Biotherapeutics Inc (SABS) | $165.07 Million | 0.00% | 0.11x | $77.80 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |